In a recent study published in Diseases, Models and Mechanisms, Professor Robin SB Williams from the University of London's College of Biological Sciences discovered a way in which curcumin might work, and he found the same effect. A more bioavailable analog.
Williams said: "For thousands of years, natural substances from plants have been used as medicines, but we don't usually know how they work. What we want to do is to explore how curcumin affects cell function."
The researchers used an amoeba (Amoeba) to study the effects of curcumin and related substances on amoeba. Two genes are known to be essential for the effect of curcumin, which has been found to be associated with Alzheimer's disease and cancer. The researchers also found that more soluble compounds associated with curcumin can work in the same way.
Experiment without animals
These innovative experiments can help people better understand curcumin and its effects, including how to treat it. “One of the main problems is that the bioavailability of curcumin is too low,” said research lead author Dr Marco Cocorocchio. “Bioavailability is the proportion of drugs that your body can use after digesting the drug. Because the bioavailability of curcumin is too low, it is difficult to know what effect curcumin has. These experiments have found that curcumin has a positive effect. The effect, but we also need to study how we will use it."
Professor Williams is the world leader in biotesters who do not use animals. He said: "Traditional drug and toxicology studies use animals as models to study what happens in humans, but concerns about the use of animals in research have prompted researchers. Exploring new methods. We have developed a new approach: using amoeba, so there is no need to use animals."
The project will focus research on the use of curcumin and related compounds with higher bioavailability to treat cancer and Alzheimer's disease.